Chelsea Counsel Co. Has $6.74 Million Stake in Johnson & Johnson (NYSE:JNJ)

Share It:

ChatGPT Perplexity WhatsApp LinkedIn X Grok Google AI

Chelsea Counsel Co. lessened its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 8.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,268 shares of the company’s stock after selling 3,635 shares during the period. Johnson & Johnson makes up about 4.2% of Chelsea Counsel Co.’s investment portfolio, making the stock its 4th largest holding. Chelsea Counsel Co.’s holdings in John Johnson were worth $6,742,000 as of its most recent filing with the Securities & Exchange Commission.

→ Elon Musk Claims Solar Will Soon Power the World (From Investing Trends)

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD boosted its stake in Johnson & Johnson by 18.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock valued at $4,370,793,000 after purchasing an additional 3,912,430 shares during the last quarter. FMR LLC boosted its stake in Johnson & Johnson by 20.8% during the 2nd quarter. FMR LLC now owns 18,725,049 shares of the company’s stock valued at $3,323,883,000 after purchasing an additional 3,229,032 shares during the last quarter. GQG Partners LLC boosted its stake in Johnson & Johnson by 64.4% during the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock valued at $1,151,931,000 after purchasing an additional 2,547,378 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in Johnson & Johnson by 52.2% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock valued at $1,083,329,000 after purchasing an additional 2,093,392 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its stake in Johnson & Johnson by 37.2% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock valued at $1,179,219,000 after purchasing an additional 1,805,632 shares during the last quarter. Institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Trading Down 0.1 %

Shares of JNJ stock opened at $169.53 on Friday. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to- equity ratio of 0.37. The stock’s 50-day moving average price is $176.15 and its 200-day moving average price is $171.37. The stock has a market capitalization of $443.23 billion, a price-to-earnings ratio of 23.61, a price-to -earnings-growth ratio of 3.28 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.49 by $0.06. The company had revenue of $23.79 billion during the quarter, compared to analyst estimates of $23.44 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The firm’s revenue was up 1.9% on a year-over-year basis. During the same quarter last year, the business posted $2.60 earnings per share. Equities research analysts predict that Johnson & Johnson will post 10.04 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be given a $1.13 dividend. The ex-dividend date of this dividend is Friday, February 17th. a $4.52 annualized dividend and a yield of 2.67%. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on JNJ shares. Sanford C. Bernstein dropped their price target on Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Citigroup raised their price target on $0 Johnson1 & Johnson0 from $0 Johnson9. to $205.00 and gave the stock a “buy” rating in a research note on Monday, December 12th. Credit Suisse Group began coverage on Johnson & Johnson in a research note on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price target on the stock. Atlantic Securities lowered their target price on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 19th. Finally, Bank of America lowered their target price on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research report on Friday, October 14th. Seven investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $182.42.

Insider Buying and Selling

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. completion of the transaction, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news Johnson & Johnson , CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the transaction chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $171.18, for a total value of $6,033,410.28. Following, the transaction vice president now owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The disclosure for this sale can be found here. Over the last quarter, insiders sold 277,886 shares of company stock worth $48,550,549. Corporate insiders own 0.35% of the company’s stock .

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Subscribe to Updates

What's Hot